SecBot SecBot
8-K ·Filed Aug 6, 2026

TARS

Tarsus Pharmaceuticals, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed3mo ago SEC0001819790-26-000060
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▲ Bullish

The acquisition is a significant strategic bet on a high-potential but early-stage asset. Traders should monitor the HSR clearance timeline and any updates on the NORTHSTAR trial enrollment. The 2-month lock-up on Alkeus stockholders limits near-term overhang, but the registration rights agreement signals eventual resale. Watch for potential financing needs given the $270M cash outlay.

DirectionBullish
Confidencehigh
Horizonmonths

ALK-001

● Neutral Named in this 8-K
Impact
Phase
Phase 3
Time to market
If the Phase 3 NORTHSTAR trial succeeds, potential FDA approval would likely follow in 2030 or later, given topline data is not expected until H2 2029.
Next catalyst
None dated

What to watchALK-001 has no near-term binary catalyst, the Phase 3 NORTHSTAR topline readout is not expected until H2 2029. TARS stock will be driven primarily by XDEMVY commercial execution and nearer-term pipeline catalysts (TP-04, TP-05) over the next 12 months. Monitor the Alkeus acquisition close and any early NORTHSTAR enrollment updates, but do not trade TARS on ALK-001 expectations alone.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$65.33
T+0 close · Aug 6, 2026 · via day close
Latest settled
+14.57%
T+60 · $74.85
Vs SPY
+16.24%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $65.33entry
  2. T+1 · 3mo ago −0.83%α −1.44% · $64.79
  3. T+5 · 3mo ago +5.43%α +4.22% · $68.88
  4. T+20 · 3mo ago +27.36%α +26.76% · $83.21
  5. T+60 · 18d ago +14.57%α +16.24% · $74.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tarsus Pharmaceuticals announced a definitive agreement to acquire Alkeus Pharmaceuticals for ~$450M upfront ($270M cash + $180M stock) plus up to $350M in milestones and low-single-digit royalties on gildeuretinol net sales. Gildeuretinol is a Phase 3 oral therapy for Stargardt disease, a large inherited retinal disease with no FDA-approved therapy. The deal adds a potential blockbuster pipeline asset but carries significant execution risk given top-line data is not expected until H2 2029 and the upfront cash consideration represents a substantial portion of Tarsus's $2.6B market cap.

Key Financial Metrics

Deal Value
$450.0M
Deal Type
acquisition

Key Facts

  • Tarsus to acquire Alkeus for ~$450M upfront ($270M cash + $180M stock at $61.38/share)
  • Up to $350M in additional milestone payments upon regulatory approval and first commercial sale
  • Low-single-digit tiered descending royalties on worldwide gildeuretinol net sales
  • Gildeuretinol is a Phase 3 oral therapy for Stargardt disease with Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations
  • Top-line Phase 3 NORTHSTAR data expected in the second half of 2029
  • Acquisition expected to close in 2026, subject to HSR clearance and customary conditions
  • Alkeus stockholders subject to a 2-month lock-up on stock consideration, with additional volume-based selling limitations for 3 months thereafter
  • Deal not contingent on financing
  • Tarsus issued ~2.93M shares as stock consideration (based on $61.38/share)

Financial Impact

Upfront consideration of ~$450M ($270M cash + $180M stock) plus up to $350M in milestones and tiered royalties. Cash component represents ~10.4% of Tarsus's $2.6B market cap.

cashdilutionrevenuer&d_expenses

Risk Factors

  • Top-line data not expected until H2 2029, long wait for catalyst
  • Cash consideration of $270M is material relative to $2.6B market cap
  • Phase 3 trial risk, Stargardt disease has no approved therapies, endpoint uncertainty
  • Integration risk with existing pipeline (IRX-101, TP-04, TP-05)
  • Potential shareholder dilution from milestone-related stock issuance
  • Regulatory approval risk for a novel oral therapy in a rare disease

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001819790-26-000060
Document: acquisitionannouncementf.htm0001819790-26-000060
Document: 0001819790-26-000060-index-headers.html0001819790-26-000060
Document: 0001819790-26-000060-index.html0001819790-26-000060
Document: 0001819790-26-000060.txt0001819790-26-000060

Track record

21 reports on TARS

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +13.44% at T+60 after the Mar 16, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 13, 20263d ago 144 Neutral 2/10 Entry $76.56 Now $78.68 +2.78% settles Nov 23
  2. Nov 5, 202611d ago 3 Neutral 2/10 Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
  3. Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
  4. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  5. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
  6. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
  7. Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  8. Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
  10. Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026